Open AccessErythrocyte adaptive metabolic reprogramming under physiological and pathological hypoxia
Author(s) -
Angelo D’Alessandro,
Yang Xia
Publication year - 2020
Publication title -
current opinion in hematology/current opinion in hematology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 97
eISSN - 1080-8213
pISSN - 1065-6251
DOI - 10.1097/moh.0000000000000574
Subject(s) - adenosine , biology , hypoxia (environmental) , purinergic receptor , erythropoiesis , adenosine receptor , microbiology and biotechnology , pharmacology , medicine , endocrinology , biochemistry , chemistry , receptor , anemia , organic chemistry , oxygen , agonist
The erythrocyte is the most abundant cell type in our body, acting as both a carrier/deliverer and sensor of oxygen (O2). Erythrocyte O2 delivery capacity is finely regulated by sophisticated metabolic control. In recent years, unbiased and robust human metabolomics screening and mouse genetic studies have advanced erythroid research revealing the differential role of erythrocyte hypoxic metabolic reprogramming in normal individuals at high altitudes and patients facing hypoxia, such as sickle cell disease (SCD) and chronic kidney disease (CKD). Here we summarize recent progress and highlight potential therapeutic possibilities.